Mineralys Therapeutics, Inc. (MLYS) Stock Price & Analysis
Mineralys Therapeutics, Inc. (MLYS) closed at USD 21.47 on Thursday, October 22, 2026, up 1.75% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 21.1; the Oct 22, 2026 session ranged USD 20.7–21.6 on volume of 824,559 shares. Market capitalization is $1.90B, with a 52-week range of USD 20.12–47.65 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MLYS.md
Key facts (MLYS)
- Analysts: Buy (mean 2.18 on a 1–5 scale) (11 analysts), mean target USD 46.33 (range 29–56).
- Total return with dividends: 1Y -47.4% vs S&P 500 +14.9%; 5Y +16.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD -0.54, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MLYS)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Operating income | -$31.5M | -$84.7M | -$192M | -$171M | -$371M |
| Net income | -$29.8M | -$71.9M | -$178M | -$155M | -$350M |
| EPS (diluted) | -$5.77 | -$1.99 | -$3.66 | -$2.29 | — |
| Free cash flow | — | -$81.2M | -$166M | -$142M | — |
| Cash + short-term investments | $87.7M | $237M | $198M | $657M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MLYS)
P/B 3.5x · Earnings yield -18.42% · Net cash $661M · EV $1.24B
Analysts (MLYS)
Consensus Buy (mean 2.18 on a 1–5 scale), 11 analysts; mean target USD 46.33 (low 29, high 56).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiated | Neutral | $29 |
| 2026-10-12 | HC Wainwright & Co. | Reiterated | Buy | $56 |
Total return (dividends reinvested) (MLYS)
| 1Y (from 2025-10-23) | 5Y (from 2023-02-06) | |
|---|---|---|
| Total return | -47.4% | +16.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -47.5% | +4.2% |
| Volatility (annualized) | 59.6% | 73.5% |
| Max drawdown | -57.1% (Nov 2025→Oct 2026) | -67.2% (Feb 2023→Nov 2023) |
MLYS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.54 | $-0.56 | -4.3% | $0 | 8 |
| Next quarter (ends Dec 2026) | $-0.59 | $-0.63 | -6.8% | $0 | 8 |
| Current fiscal year (ends Dec 2026) | $-4.43 | $-2.24 | +98.0% | $0 | 8 |
| Next fiscal year (ends Dec 2027) | $-2.46 | $-2.10 | +17.2% | $87.8M | 9 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 21.47 |
|---|---|
| Change | ▲ 1.75% (up) |
| Previous Close | USD 21.1 |
| Open | USD 21 |
| Day Range | USD 20.7 – 21.6 |
| 52-Week Range | USD 20.12 – 47.65 |
| Volume | 824,559 shares |
| Market Cap | $1.90B |
| Exchange | NMS |
Technical Analysis (MLYS)
Nexqual's technical model rates MLYS "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.01 (neutral) |
| vs SMA50 | Below (USD 25.46) |
| MACD | -1.44 (negative) |
Analyst Ratings (MLYS)
Wall Street analysts rate MLYS "Buy" based on 11 analysts, with a mean price target of USD 46.33 (range USD 29–56), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 46.33 |
| High Target | USD 56 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (MLYS)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.54 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.85 vs est -0.54 ▼ miss |
| 2026-03-31 | USD -0.47 vs est -0.44 ▼ miss |
| 2025-12-31 | USD -0.4 vs est -0.52 ▲ beat |
| 2025-09-30 | USD -0.52 vs est -0.61 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (MLYS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -80.88% |
| Debt / Equity | 0.18 |
| Current Ratio | 34.46 |
| Total Cash | $661.41M |
| Total Debt | $97.62M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (MLYS)
Nexqual rates Mineralys Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $661M cash and investments, no debt (Jun 2026, SEC) |
| Cash Flow | Weak — Operating cash flow -$142M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -81%, ROA -46.2% |
Ownership (MLYS)
| Insider Ownership | +0.70% |
|---|---|
| Institutional Ownership | +117.48% |
| Shares Outstanding | 88.41M |
| Float | 66.60M |
| Short % of Float | +10.57% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (MLYS)
Mineralys Therapeutics, Inc. is led by Jon Congleton, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| President, CEO & Director | Jon Congleton |
|---|---|
| Founder & Executive Director | Brian Taylor Slingsby M.D., M.P.H. |
| CFO & Secretary | Adam Scott Levy |
| Senior Vice President of CMC | Robert McKean |
| Senior Vice President of Quality Assurance | Danielle Mahoney |
Major Backers & Investors (MLYS)
Notable institutional backers of Mineralys Therapeutics, Inc. include Catalys Pacific, LLC, RA Capital Management, L.P., Samsara BioCapital, LLC, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Catalys Pacific, LLC | 8.94% |
| RA Capital Management, L.P. | 8.7% |
| Samsara BioCapital, LLC | 6.64% |
| FMR, LLC | 5.1% |
| Deerfield Management Company, L.P | 4.48% |
| Laurion Capital Management, LP | 2.83% |
| Fidelity | 2.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.66% |
| State Street | 4.68% |
| Vanguard Group | 3.12% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt